Solventum Stock (SOLV)

XNYS Alert Compare

Health Care · Fundamental analysis

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Solventum was spun off from the conglomerate 3M in 2024 and combines its former healthcare division. The company makes wound care products, dental products, filters for drug manufacturing and software for hospitals. Customers are hospitals and practices worldwide. As of Oct 11, 2026

Fact sheet (from the annual report) Medical instruments · Eagan, USA

Solventum is a global healthcare company that develops and markets solutions based on materials science, data science and digital technology. The MedSurg segment offers negative pressure wound therapy, wound dressings, surgical supplies, medical tapes and stethoscopes. Dental Solutions supplies dental and orthodontic products such as brackets, aligners, restorative cements and adhesives. Health Information Systems offers health systems software for clinical documentation and automated coding, designed for accurate reimbursement. In 2025 Solventum acquired the life sciences company Acera Surgical and divested its purification and filtration business. Customers range from hospitals to local practices and are served directly, through distributors and online.

Automatically summarized from SEC annual report (10-K, filed Feb 27, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −1.5%
  • 7 days −5.1%
  • 30 days −2.5%
  • 1 year +6.3%
Day range (last trading day)
−0.4%Price at 12% of the range+3.1%
52-week range
−26.2%Price at 70% of the range+11.4%
Distance from the all-time high
−12.0%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis

Fundamental analysis

Solventum · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 27, 2026.

For you first Dividend

The company pays no dividend.

For you first Valuation

There is currently no comparison of the P/E with its own history (for example too few comparable annual values).

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
1 of 3
criteria with data met
Revenue per year (3 y)
+0.8%
EPS per year (3 y)
+4.5%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
5 of 7
criteria with data met
Net margin
18.7%
Cash flow ÷ profit
0.24x
backed from 1.0 · 3 years: 1.03x

For you first Trading

The overview of this stock shows the trend by timeframe.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 5 of 7 met · 1 without data

  • met: Gross margin above 40% 53.5%
  • met: Operating margin above 15% 26.2%
  • met: Net margin above 10% 18.7%
  • met: Return on equity above 15% 30.8%
  • not met: Free cash flow margin above 10% −0.1%
  • no data: Profit in each of the last 5 fiscal years fewer than 5 fiscal years reported
  • not met: Free cash flow positive in each of the last 3 fiscal years 2 of 3
  • met: Equity ratio above 30% 35.3%
Gross margin

53.5% Fiscal year 2025

Rank 60 of 100: higher than 60% of 370 peers (All). medium.

Rank 34 of 100: higher than 34% of 49 peers (Sector). medium.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Operating margin

26.2% Fiscal year 2025

Rank 79 of 100: higher than 79% of 470 peers (All). strong.

Rank 84 of 100: higher than 84% of 54 peers (Sector). strong.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

18.7% Fiscal year 2025

Rank 74 of 100: higher than 74% of 584 peers (All). strong.

Rank 71 of 100: higher than 71% of 63 peers (Sector). strong.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

30.8% Fiscal year 2025

Rank 81 of 100: higher than 81% of 544 peers (All). strong.

Rank 82 of 100: higher than 82% of 54 peers (Sector). strong.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

10.9% Fiscal year 2025 (total assets at year end)

Rank 78 of 100: higher than 78% of 594 peers (All). strong.

Rank 71 of 100: higher than 71% of 63 peers (Sector). strong.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

35.3% Fiscal year 2025

Rank 47 of 100: higher than 47% of 595 peers (All). medium.

Rank 34 of 100: higher than 34% of 63 peers (Sector). medium.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

−0.1% Fiscal year 2025

Rank 17 of 100: higher than 17% of 465 peers (All). weak.

Rank 7 of 100: higher than 7% of 61 peers (Sector). weak.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

−10.0M USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 1 of 3 met · 4 without data

  • not met: Over 3 years, revenue grew by more than 5% per year +0.8%
  • no data: Over 5 years, revenue grew by more than 5% per year no comparable figures over 5 years
  • no data: Over 10 years, revenue grew by more than 5% per year no comparable figures over 10 years
  • not met: Over 3 years, EPS grew by more than 5% per year +4.5%
  • no data: Over 5 years, EPS grew by more than 5% per year not computable (loss in the first year, or figures missing)
  • no data: Revenue rose in at least 4 of the last 5 fiscal years fewer than 6 fiscal years reported
  • met: Revenue rose in the last fiscal year +0.9%
Revenue growth 3 years

+0.8% per year

Rank 25 of 100: higher than 25% of 578 peers (All). weak.

Rank 25 of 100: higher than 25% of 62 peers (Sector). weak.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

EPS growth 3 years

+4.5% per year

Rank 42 of 100: higher than 42% of 437 peers (All). medium.

Rank 49 of 100: higher than 49% of 54 peers (Sector). medium.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 0 of 1 met · 6 without data

  • not met: Pays a dividend no dividend per share reported for the last fiscal year
  • no data: Payout ratio at most 60% of earnings pays no dividend
  • no data: Dividend paid in each of the last 5 fiscal years pays no dividend
  • no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
  • no data: Dividend per share higher than 5 years ago pays no dividend
  • no data: Free cash flow per share covers the dividend pays no dividend
  • no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend

Financial strength 3 of 5 met · 1 without data

  • not met: Piotroski F-Score at least 7 of 9 5 of 9
  • met: Long-term debt no higher than equity 1.00
  • met: Current assets cover current liabilities 1.23
  • met: Positive equity 5.0B USD
  • no data: In 5 years, share count up by at most 5% no comparable share count 5 years ago
  • not met: Free cash flow positive in the last fiscal year −10.0M USD
Piotroski F-Score

5 of 9 Fiscal year 2025

Rank 22 of 100: higher than 22% of 310 peers (All). weak.

Rank 17 of 100: higher than 17% of 47 peers (Sector). weak.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

1.00 at fiscal year end

Rank 31 of 100: lower than 31% of 486 peers (All). weak.

Rank 15 of 100: lower than 15% of 50 peers (Sector). weak.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.23 at fiscal year end

Rank 44 of 100: higher than 44% of 513 peers (All). medium.

Rank 28 of 100: higher than 28% of 63 peers (Sector). weak.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

+1.5% in 3 years

No rank: too few peers or not computed yet.

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • not met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • not met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • not met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 3 years (+0.8% per year), more slowly than the sector median.
  • Light green: Net income (total) grew over 3 years (+5.0% per year), at least as fast as the sector median; per share +4.5% per year.
  • Light green: Net margin 18.7%, above the sector median (13.9%).
  • Light yellow: Debt higher than usual in the sector.
  • Light green: Profit in each of the last 4 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 8.1B USD · Net income 1.3B USD · Net margin 16.5%
  2. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 8.2B USD · Net income 1.3B USD · Net margin 16.4%
  3. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 8.3B USD · Net income 479.0M USD · Net margin 5.8%
  4. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 8.3B USD · Net income 1.6B USD · Net margin 18.7%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 8.3B USD · Net income 1.6B USD · Net margin 18.7%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 −7.0% vs. the same quarter a year earlier.

Revenue 12 months vs. prior 12
−2.8%
12 months: 8.2B USD · Fiscal year 2025: +0.9%
Net margin 12 months
1.9%
Fiscal year 2025: 18.7%
Free cash flow margin 12 months
0.0%
Fiscal year 2025: −0.1%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 8.3B USD + year to date to Sep 30, 2026 6.2B USD − same period a year earlier to Sep 30, 2025 6.3B USD = 8.2B USD
  • Net income: fiscal year to Dec 31, 2025 1.6B USD + year to date to Sep 30, 2026 93.0M USD − same period a year earlier to Sep 30, 2025 1.5B USD = 156.0M USD
  • Operating cash flow: fiscal year to Dec 31, 2025 369.0M USD + year to date to Sep 30, 2026 215.0M USD − same period a year earlier to Sep 30, 2025 274.0M USD = 310.0M USD
  • Capital expenditure: fiscal year to Dec 31, 2025 379.0M USD + year to date to Sep 30, 2026 247.0M USD − same period a year earlier to Sep 30, 2025 316.0M USD = 310.0M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 261.9B−7.0%−12.0M−0.6%
Apr–Jun 262.2B+2.2%92.0M4.2%
Jan–Mar 262.0B−3.0%13.0M0.6%
Oct–Dec 25*2.0B−3.7%63.0M3.2%
Jul–Sep 252.1B+0.7%1.3B60.4%
Apr–Jun 252.2B+3.8%90.0M4.2%
Jan–Mar 252.1B+2.7%137.0M6.6%
Oct–Dec 24*2.1B+1.9%31.0M1.5%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Nov 5, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is well above the cash coming in from the business; interest is well covered.

Cash flow ÷ profit
0.24x
backed from 1.0 · 3 years: 1.03x
Interest coverage
6.3x
well covered from 5 · net interest expense
Tax rate
9.2%
for information only · 3 years: 15.2%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 369.0M USD ÷ Net income 1.6B USD = 0.24x
  • Operating income 2.2B USD ÷ net interest expense 347.0M USD = 6.3x
  • Taxes 157.0M USD ÷ profit before tax 1.7B USD = 9.2%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20250.24x6.3x9.2%
20242.47x2.8x21.0%
20231.42x–19.3%
20221.25x–20.6%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 4 fiscal years no loss year; no year with lower revenue across 3 years with a prior-year figure.

Loss years
0 of 4
net income below zero
Years with lower revenue
0 of 3
revenue below the prior year
Net margin range
12.9 percentage points
from 5.8% to 18.7%
Net margin by fiscal year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+0.9%18.7%
2024+0.7%5.8%
2023+0.8%16.4%
2022–16.5%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2022–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 53.5 USD gross profit, 26.2 USD operating income and 18.7 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue8.3B USD100.0%
Gross profit4.5B USD53.5%
Cost of revenue3.9B USD46.5%
Operating income2.2B USD26.2%
Research & development739.0M USD8.9%
Other operating expenses1.5B USD18.4%
Net income1.6B USD18.7%
Taxes157.0M USD1.9%
Interest & other468.0M USD5.6%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin rose in 3 years from 20.8% to 26.2%.

Gross marginOperating marginNet margin
  1. Fiscal year 2022: Gross margin 57.7% · Operating margin 20.8% · Net margin 16.5%
  2. Fiscal year 2023: Gross margin 57.3% · Operating margin 20.6% · Net margin 16.4%
  3. Fiscal year 2024: Gross margin 55.6% · Operating margin 12.6% · Net margin 5.8%
  4. Fiscal year 2025: Gross margin 53.5% · Operating margin 26.2% · Net margin 18.7%

Returns

Return on equity rose in 3 years from 11.4% to 30.8%.

Return on equityReturn on assets
  1. Fiscal year 2022: Return on equity 11.4% · Return on assets not available
  2. Fiscal year 2023: Return on equity 11.5% · Return on assets 9.7%
  3. Fiscal year 2024: Return on equity 16.2% · Return on assets 3.3%
  4. Fiscal year 2025: Return on equity 30.8% · Return on assets 10.9%

Equity and long-term debt

The equity ratio fell in 2 years from 83.7% to 35.3%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2022: Equity 11.7B USD · Long-term debt not available
  2. Fiscal year 2023: Equity 11.7B USD · Long-term debt 0.0 USD
  3. Fiscal year 2024: Equity 3.0B USD · Long-term debt 8.0B USD
  4. Fiscal year 2025: Equity 5.0B USD · Long-term debt 5.0B USD

Liquidity (current ratio)

The current ratio fell in 2 years from 1.46 to 1.23.

Current ratio
  1. Fiscal year 2022: Current ratio not available
  2. Fiscal year 2023: Current ratio 1.46
  3. Fiscal year 2024: Current ratio 1.20
  4. Fiscal year 2025: Current ratio 1.23

Cash flow

Free cash flow fell in 3 years from 1.4B USD to −10.0M USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2022: Operating cash flow 1.7B USD · Capital expenditure 251.0M USD · Free cash flow 1.4B USD
  2. Fiscal year 2023: Operating cash flow 1.9B USD · Capital expenditure 290.0M USD · Free cash flow 1.6B USD
  3. Fiscal year 2024: Operating cash flow 1.2B USD · Capital expenditure 380.0M USD · Free cash flow 805.0M USD
  4. Fiscal year 2025: Operating cash flow 369.0M USD · Capital expenditure 379.0M USD · Free cash flow −10.0M USD

Share count

The share count rose in 3 years by 1.5% – more new shares were issued than repurchased (dilution).

Diluted share count
  1. Fiscal year 2022: Diluted share count 172.7M
  2. Fiscal year 2023: Diluted share count 172.7M
  3. Fiscal year 2024: Diluted share count 173.7M
  4. Fiscal year 2025: Diluted share count 175.3M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Revenue

Revenue stayed roughly the same in 3 years (8.3B USD).

SOLV in USD
  1. Fiscal year 2022: SOLV 8.1B USD
  2. Fiscal year 2023: SOLV 8.2B USD
  3. Fiscal year 2024: SOLV 8.3B USD
  4. Fiscal year 2025: SOLV 8.3B USD

Earnings per share

Earnings per share rose in 3 years from 7.78 USD to 8.88 USD.

SOLV USD per share
  1. Fiscal year 2022: SOLV 7.78 USD
  2. Fiscal year 2023: SOLV 7.79 USD
  3. Fiscal year 2024: SOLV 2.76 USD
  4. Fiscal year 2025: SOLV 8.88 USD

Share count

The share count rose in 3 years by 1.5% – more new shares were issued than repurchased (dilution).

SOLV
  1. Fiscal year 2022: SOLV 172.7M
  2. Fiscal year 2023: SOLV 172.7M
  3. Fiscal year 2024: SOLV 173.7M
  4. Fiscal year 2025: SOLV 175.3M

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The company pays no dividend.

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

There is currently no comparison of the P/E with its own history (for example too few comparable annual values).

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
none pays no dividend

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Solventum next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison SOLV, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
MDT Medtronic 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
SOLV Solventum this stock 8.3B USD –53.5%26.2%18.7%30.8%35.3%−0.1%5/9
MRNA Moderna 1.9B USD +19.3%55.3%−158.1%−145.2%−32.6%70.1%−106.2%2/9
Median of the sector 27 symbols 44.3B USD +8.5%67.2%18.2%14.6%14.3%38.4%14.7%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector SOLV next to ISRG – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+0.8% per year, last 3 years

Sector Health Care: median +5.6% (25 symbols)

What does this mean? Revenue: over 3 years it grew by 0.8% per year on average, but more slowly than the median company in the sector (+5.6%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+5.0% per year, last 3 years

Sector Health Care: median +4.6% (22 symbols)

per share: +4.5% per year (3 years, split-adjusted)

What does this mean? Total net income: over 3 years it grew by 5.0% per year on average – at least as fast as the median company in the sector (+4.6%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

18.7% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 18.69 USD remained as profit – at least as much as the median company in the sector (13.9%).

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

0.95 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.95 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

4 of 4 fiscal years with a profit

What does this mean? In 4 of the last 4 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
8.3B USD
Revenue vs. prior year
+0.9%
Net income (FY)
1.6B USD
Net income vs. prior year
+224.8%
EPS (FY)
8.88 USD
Superinvestors holding
2 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 27, 2026 · Balance sheet Sep 30, 2026 (filed Nov 5, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 8.3B1.6B 18.7% 8.88 – –
2024Dec 31, 2024 8.3B479.0M 5.8% 2.76 – –
2023Dec 31, 2023 8.2B1.3B 16.4% 7.79 – –
2022Dec 31, 2022 8.1B1.3B 16.5% 7.78 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 1.9B−12.0M −0.6% −0.07 – –
Q2/26Jun 30, 2026 2.2B92.0M 4.2% 0.53 – –
Q1/26Mar 31, 2026 2.0B13.0M 0.6% 0.07 – –
Q4/25*Dec 31, 2025 2.0B63.0M 3.2% – – –
Q3/25Sep 30, 2025 2.1B1.3B 60.4% 7.22 – –
Q2/25Jun 30, 2025 2.2B90.0M 4.2% 0.51 – –
Q1/25Mar 31, 2025 2.1B137.0M 6.6% 0.78 – –
Q4/24*Dec 31, 2024 2.1B31.0M 1.5% – – –
Q3/24Sep 30, 2024 2.1B122.0M 5.9% 0.70 – –
Q2/24Jun 30, 2024 2.1B89.0M 4.3% 0.51 – –
Q1/24Mar 31, 2024 2.0B237.0M 11.8% 1.37 – –
Q4/23*Dec 31, 2023 2.0B272.0M 13.4% – – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $00 people $0
6 months $00 people $00 people $0
12 months $100.3K1 person $00 people +$100.3K

Latest transactions

  • Mar 10, 2026 Wendell Amy McBride Director Open-market purchase 1,475 shares · $100.3K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Solventum?

All superinvestor portfolios

2 of 26 tracked superinvestors report a position.

Superinvestors with a position in Solventum, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Bridgewater Associates 0.1% +91.0% increased Q3 2026
Paul Tudor Jones Tudor Investment Corp < 0.1% −92.6% reduced Q3 2026

Sold out in the latest quarter: Steve Cohen.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on SOLV yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: SOLV

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close